about
Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisibEndothelin-1 promotes survival and chemoresistance in chronic lymphocytic leukemia B cells through ETA receptorPhysical contact with endothelial cells through β1- and β2- integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells.Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia.The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation.ANGPT2 promoter methylation is strongly associated with gene expression and prognosis in chronic lymphocytic leukemia.Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors.Increased angiogenesis induced by chronic lymphocytic leukemia B cells is mediated by leukemia-derived Ang2 and VEGF.Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia.Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor.Gene expression profiling of acute promyelocytic leukaemia identifies two subtypes mainly associated with flt3 mutational status.Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia.Increased expression of angiopoietin-2 characterizes early B-cell chronic lymphocytic leukemia with poor prognosis.Angiopoietin-2 expression in B-cell chronic lymphocytic leukemia: association with clinical outcome and immunoglobulin heavy-chain mutational status
P50
Q27025812-B6E53E14-31CA-4D14-85B9-35995F2ACE57Q28539394-52BC66DB-93D0-4994-90B5-C98DD7BF59A0Q36006453-F4E3ACE0-9ADF-4880-8FCF-9F2C0491EAB6Q36715966-C3107179-8D6D-42C8-AECD-1CEBF0798271Q36967153-56F30E66-3C3A-4447-9372-AC0057D2BFC9Q37192643-9E852CBF-80B5-4EFD-A383-8DD6B64C81D6Q38603785-D07E63B9-56C5-4FBA-86C4-C9CCE98AA3F4Q39962023-3E4C1664-3EF8-4846-BC5C-EF9774D1DA9BQ44930034-FF2E5F32-755D-4964-BD2A-E9E78880F824Q45958805-46361337-8887-4D2F-A617-6A8BE1657376Q46562795-56991AD7-21D8-46BA-8DFF-2CCA84F86DEEQ46790741-36DB8F7B-3C9A-45CC-8BB4-ECBE0CE9560BQ53330290-2FCA6926-5531-43CC-9AD3-A4E288EACF0DQ53522638-599F1CF8-5CE0-47B3-BC79-35AC872CF8A3Q60584738-2C22799F-B446-425D-9A20-A2AE9FB35C44
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Silvia Martinelli
@ast
Silvia Martinelli
@en
Silvia Martinelli
@es
Silvia Martinelli
@nl
Silvia Martinelli
@sl
type
label
Silvia Martinelli
@ast
Silvia Martinelli
@en
Silvia Martinelli
@es
Silvia Martinelli
@nl
Silvia Martinelli
@sl
prefLabel
Silvia Martinelli
@ast
Silvia Martinelli
@en
Silvia Martinelli
@es
Silvia Martinelli
@nl
Silvia Martinelli
@sl
P1053
J-9080-2016
P106
P1153
23493251400
P21
P31
P3829
P496
0000-0002-2856-6327